Back
Protagonist Therapeutics Vs. Akebia Therapeutics Industry Stock Comparison
Buy
54
PTGX
Protagonist Therapeutics
Last Price:
25.54
Seasonality Move:
28.29%
Sell
44
AKBA
Akebia Therapeutics
Last Price:
1.30
Seasonality Move:
7.48%
Buy
54
Protagonist Therapeutics (PTGX)
is a Buy
Is Protagonist Therapeutics a Buy, Sell or Hold?
- The current Protagonist Therapeutics [PTGX] share price is $25.54. The Score for PTGX is 54, which is 8% above its historic median score of 50, and infers lower risk than normal.
- PTGX is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
44
Akebia Therapeutics (AKBA)
is a Sell
Is Akebia Therapeutics a Buy, Sell or Hold?
- The current Akebia Therapeutics [AKBA] share price is $1.24. The Score for AKBA is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.
- AKBA is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
PTGX Stock Price Chart
What is Protagonist Therapeutics's stock price today?
-
The Protagonist Therapeutics share price today is $25.54
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and PTGX is experiencing slight selling pressure.
AKBA Stock Price Chart
What is Akebia Therapeutics's stock price today?
-
The Akebia Therapeutics share price today is $1.24
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and AKBA is experiencing selling pressure, which indicates risk of future bearish movement.
PTGX Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.78 | Sell |
| Relative Strength Index (14 RSI): | 42.33 | Sell |
| Chaikin Money Flow: | -6664 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (25.53 - 28.19) | Sell |
| Bollinger Bands (100): | (23.22 - 29.1) | Sell |
AKBA Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.09 | Sell |
| Relative Strength Index (14 RSI): | 32.53 | Sell |
| Chaikin Money Flow: | -2592955 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (1.28 - 1.68) | Sell |
| Bollinger Bands (100): | (1.26 - 1.72) | Sell |
PTGX Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 25.65 | Sell |
| 20-day SMA: | 26.49 | Sell |
| 50-day SMA: | 28.15 | Sell |
| 200-day SMA: | 21.88 | Buy |
| 8-day EMA: | 25.57 | Sell |
| 20-day EMA: | 26.33 | Sell |
| 50-day EMA: | 26.87 | Sell |
| 200-day EMA: | 23.56 | Buy |
AKBA Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.32 | Sell |
| 20-day SMA: | 1.41 | Sell |
| 50-day SMA: | 1.56 | Sell |
| 200-day SMA: | 1.32 | Sell |
| 8-day EMA: | 1.32 | Sell |
| 20-day EMA: | 1.41 | Sell |
| 50-day EMA: | 1.49 | Sell |
| 200-day EMA: | 1.33 | Sell |
Protagonist Therapeutics Earnings Growth & PTGX Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.10 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.87 per share, and a decrease next year of $0.23 per share.
Akebia Therapeutics Earnings Growth & AKBA Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.00 per share, an increase next quarter of $0.10 per share, an increase this year of $0.05 per share, and an increase next year of $0.05 per share.
Protagonist Therapeutics Technical Analysis
| Apr 18 | Apr 19 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | Apr 26 | Apr 29 | Apr 30 | May 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 18 | 19 | 22 | 23 | 24 | 25 | 26 | 29 | 30 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Akebia Therapeutics Technical Analysis
| Apr 18 | Apr 19 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | Apr 26 | Apr 29 | Apr 30 | May 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 18 | 19 | 22 | 23 | 24 | 25 | 26 | 29 | 30 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||